Eli Lilly, Biogen slip as Alzheimer's treatment fails trial

Shares of Eli Lilly are slipping as the company’s Alzheimer's drug failed a trial. Meanwhile, Biogen was counting on regulators to approve a similar drug of its own. Yahoo Finance’s Anjalee Khemlani joins Seana Smith on The Ticker to discuss.

Advertisement